Drug intelligence / Profile preview

Zhiyu Anshen

Development stage: Unknown
Lead developer: Tianjin Xuanhong Medical Technology
Administration: Oral

Overview

Zhiyu Anshen is a Traditional Chinese Medicine (TCM) granule formulation developed by Tianjin Xuanhong Pharmaceutical Technology for the treatment of depression. It is specifically indicated for patients presenting with the TCM syndrome of Liver Qi stagnation transforming into fire. The formulation is designed to soothe the liver, resolve depression, and calm the spirit (Anshen). Clinical development has progressed through Phase II trials in China, where it has been evaluated for efficacy and safety in improving depressive symptoms compared to placebo within the context of traditional diagnostic frameworks.

Other names: Zhiyu Anshen Granules治郁安神颗粒

Targets

DRD (Dopamine receptors)5-HT (Serotonin receptors)

Beyond the preview

Go deeper on Zhiyu Anshen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhiyu Anshen.

Explore the full profile